What 4 Analyst Ratings Have To Say About Definitive Healthcare
Portfolio Pulse from Benzinga Insights
Definitive Healthcare (NASDAQ:DH) has been analyzed by 4 analysts, showing a mix of ratings from bullish to indifferent. The 12-month price targets have an average of $10.5, with a recent increase from $10.33. Analysts from Barclays, Canaccord Genuity, and Stifel have adjusted their ratings and price targets, reflecting their views on the company's market conditions and performance. Definitive Healthcare, a provider of healthcare commercial intelligence, shows positive revenue growth but struggles with profitability, as indicated by its net margin and ROA.
March 01, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Definitive Healthcare has received mixed analyst ratings, with an updated average 12-month price target of $10.5. The company shows positive revenue growth but faces profitability challenges.
The mixed analyst ratings and the slight increase in the average price target suggest a neutral short-term impact on DH's stock price. The positive revenue growth is a strong point, but the profitability issues, as indicated by the net margin and ROA, could temper investor enthusiasm. The adjustments in ratings and price targets by analysts from Barclays, Canaccord Genuity, and Stifel reflect a cautious optimism, balanced by the recognition of existing financial challenges.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100